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1  | INTRODUC TION
In	2015,	 there	were	 an	estimated	71	million	persons	 chronically	
infected	 with	 hepatitis	 C	 virus	 (HCV),	 resulting	 in	 1.34	 million	
deaths	 that	 year.1	 With	 the	 global	 efforts	 of	 the	World	 Health	
Organization	 to	eradicate	HCV	by	2030,	 it	 is	 important	 to	 iden‐
tify	 individuals	at	risk	and	provide	treatment	as	soon	as	possible	
after	diagnosis.2	While	the	majority	of	infections	among	adults	in	
many	settings	are	 linked	 to	 injection	drug	use,	 the	most	 import‐
ant	source	of	paediatric	HCV	infection	is	vertical	transmission	of	




1.1 | Vertical transmission of HCV
A	 large	meta‐analysis	performed	by	Benova	et	al	 reported	a	5.8%	
risk	of	vertical	transmission	of	HCV,	resulting	in	1700	HCV‐infected	
newborns	 in	 the	USA	yearly.9,10	 In	 addition	 to	high	maternal	HCV	












and	 internal	 foetal	 monitoring	 (uterine	 or	 foetal	 scalp)	 have	 been	
reported	to	contribute	to	an	increased	risk	of	vertical	HCV	transmis‐
sion.16	Currently,	most	studies	suggest	that	the	risk	of	transmission	




Transmission	may	 be	most	 frequent	 during	 the	 peripartum	period	
(estimated	40%‐50%)	when	there	is	blood‐blood	contact	during	de‐










1.2 | Testing and consequences of HCV 
in the newborn
Although	 vertical	 transmission	 seems	 to	 be	 the	 most	 important	
source	 of	 paediatric	HCV	 infection,	 a	 retrospective	 cohort	 study	










ously,	 resulting	 in	 chronic	 paediatric	 HCV	 infection.26	 Although	
liver	injury	from	chronic	HCV	infection	generally	progresses	slowly	
early	 in	 life,	 serious	 liver	damage	can	occur	during	childhood	and	
beyond.27‐29	One	centre	reported	five	children	(out	of	91	included	
patients,	mean	age:	9	years)	with	an	accelerated	course	of	HCV	and	
early	development	of	decompensated	 liver	disease	 requiring	 liver	
transplantation,	 two	of	whom	subsequently	died.30 In addition to 
concerns	 about	 the	 physical	 health	 of	 the	 child	 with	 HCV,	 there	
may	be	high	 levels	of	distress	 in	the	family.31	Treatment	regimens	




NCT03067129,	 NCT03080415,	 NCT03487848,	 NCT03022981].	
Unfortunately,	 there	 will	 be	 no	 treatment	 available	 prior	 to	 the	
age	of	3	in	the	near	future	as	this	is	not	requested	by	the	European	
Medicines	 Agency	 (EMA).	 Therefore,	 treatment	 of	 children	 with	
vertically	 acquired	HCV	may	 be	 complicated	 as	 loss	 to	 follow‐up	
in	healthcare	later	in	life	is	likely	to	be	high,	as	is	the	case	in	some	
settings	for	HIV.33,34
1.3 | Effect of HCV on pregnancy outcome
In	addition	to	the	risk	of	vertical	HCV	transmission,	maternal	HCV	
infection	may	 increase	 the	 risk	 of	 adverse	 pregnancy	 outcomes.	
Recently,	a	protocol	has	been	published	for	a	study	which	will	un‐
dertake	 an	 extensive	 systematic	 review	 of	 pregnancy	 outcomes	
in	 women	 with	 HCV;	 results	 are	 expected	 soon.35	 Only	 a	 small	
proportion	of	available	studies	have	sufficient	power	to	adjust	for	
potential	confounding	variables	such	as	tobacco,	alcohol	and	drug	
use.	These	 studies	 report	 an	association	between	maternal	HCV	
infection	and	the	risk	of	gestational	diabetes	and	intrahepatic	chol‐
estasis	of	pregnancy.36,37	In	addition,	an	increased	risk	of	preterm	
birth	was	 reported	and	children	born	 to	women	 living	with	HCV	
were	more	likely	to	have	a	lower	birth	weight	and	to	be	small	for	
gestational	age.38‐41
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Maternal‐Foetal	 Medicine,	 have	 not	 yet	 adopted	 the	 recommen‐
dation.	 It	 is	 estimated	 that	 such	 a	 screening	 strategy,	 followed	by	
treatment	 after	 pregnancy,	 would	 be	 cost‐effective	 for	 maternal	



















2  | EFFEC T OF PREGNANCY ON 
MATERNAL E XPOSURE TO DIREC T-AC TING 
ANTIVIR AL S









each	DAA,	we	discuss	 the	 impact	of	 pregnancy	on	maternal	DAA	
exposure	by	considering	the	potential	effect	on	drug	absorption,	dis‐
tribution,	metabolism	and	excretion,	as	well	as	potential	drug‐drug	






delayed‐gastric	 emptying,	 prolonged	 gastrointestinal	 transit	 time	
and	 reduced	 gastric	 acidity,	 can	 either	 increase	 or	 decrease	 drug	
absorption.55,56	Ledipasvir	and	velpatasvir	show	pH‐dependent	ab‐
sorption,	with	a	decreased	solubility	at	a	higher	pH.	Reduced	gastric	
TA B L E  1  Overview	safety	and	pharmacokinetic	data	of	DAAs	in	pregnancy
DAA combination Genotype
Hypothetical change in maternal exposure 
(mechanism)
Safety concerns based 
on animal data
Priority to be studied in 
clinical trials in pregnancy
SOF/DAC Genotype	1‐4 ↓	DAC	exposure	(CYP3A4	induction) Yes High







GZR/ELB Genotype	1,4 ↓	GZR/	ELB	exposure	(CYP3A4	induction) No Moderate
GLE/PIB Pan‐genotypic ↓	GLE	exposure	(CYP3A4	induction) Uncertain High
Abbreviations:	DAC,	daclatasvir;	ELB,	elbasvir;	GLE,	glecaprevir;	GZR,	grazoprevir;	LDV,	ledipasvir;	PIB,	pibrentasvir;	SOF,	sofosbuvir;	VEL,	vel‐
patasvir;	VOX,	voxilaprevir.




scribed.59	 It	has	been	 shown	 that	velpatasvir	 and	 ledipasvir	 expo‐
sure	in	healthy	volunteers	treated	with	PPIs	such	as	omeprazole,	is	
reduced	up	 to	40%.60,61	Therefore,	 co‐administration	of	PPIs	with	





weight)	 determine	 drug	 distribution.	 For	 example,	 the	 increase	 in	
body	fat	during	pregnancy	is	likely	to	increase	the	volume	of	distri‐
bution	of	highly	 lipophilic	drugs,	such	as	DAAs,	which	 in	turn	may	
result	 in	 lower	 peak	 plasma	 levels,	 prolonged	 half‐life	 and	 lower	
amplitude	 of	 plasma	 concentrations	 at	 steady	 state.	 However,	 lit‐
tle	 information	 is	 available	 to	 estimate	 the	 contribution	of	 the	 in‐







unbound	 concentrations	 are	 unaffected.	 Therefore,	 it	 is	 crucial	 to	








glucuronosyltransferase	 (UGT)	 family	 have	 been	 observed.	While	
the	mechanism	 of	 the	 observed	 changes	 has	 not	 been	 identified,	
accumulated	data	suggest	that	the	changes	are	regulated	by	rising	









resulting	 in	 virological	 failure.65	 The	moderate	 pregnancy‐induced	


















QD	 when	 co‐administered	 with	 moderate	 inducers	 of	 CYP3A4A,	
as	 reductions	 in	 exposure	 of	 25%	have	 been	observed	 frequently	








excretion	 as	 parent	 drug.	 Pregnancy	 may	 alter	 the	 expression	 of	
drug	transporters	in	metabolising	and	eliminating	organs,	but	there	










is,	 however,	 unclear	whether	 this	 could	 influence	plasma	 levels	 to	
the	point	of	requiring	dose	adjustment.55,71








are	 well	 described	 in	 the	 literature.65,73	 However	 pregnancy‐in‐
duced	alterations	could	also	influence	either	HCV	and/or	HIV	drug	






pregnancy	 on	 drug	 exposure.	 A	 first	 example	 is	 efavirenz,	 com‐





using	 efavirenz.	 In	 pregnant	 women,	 an	 increase	 of	 daclatasvir	
dose	may	 also	 be	warranted	 as	 pregnancy	 also	 affects	 CYP3A4	






results	 in	 higher	 voxilaprevir	 due	 to	 inhibition	 of	 organic‐anion‐
transporting	 polypeptide	 (OATP)‐1B1,	 P‐glycoprotein	 (P‐gp)	 and	
CYP3A,	 with	 an	 AUC	GMR	 (90%	 CI)	 of	 2.43	 (2.15,	 2.75),	 but	 is	
considered	to	be	not	clinically	relevant	in	the	nonpregnant	popu‐
lation.75	During	pregnancy	twice	daily	darunavir,	 instead	of	once	
daily,	 is	 recommended	 and	 therefore	 concomitant	 use	 of	 daru‐
navir/ritonavir	 and	 sofosbuvir/velpatasvir/voxilaprevir	 should	 be	
contra‐indicated.
According	 to	 the	 guidelines,	 dolutegravir	 has	 low	 potential	
for	 DDIs	 and	 may	 therefore	 seem	 of	 particular	 interest	 for	 use	






increased	 risk	 of	 neural	 tube	 defects.	As	 the	 choice	 for	HCV	 as	
well	as	cART	is	mainly	dependent	on	local	drug	availability,	which	
is	limited	in	low‐income	countries,	it	might	not	be	possible	to	pre‐
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3.1 | Placental handling in human pregnancy





possible	 research	 strategies	 highlight	 that	 times	 are	 changing.78,79 
To	our	knowledge,	information	on	DAA	exposure	during	pregnancy	





3.2 | Placental handling in pre‐clinical research
Studies	on	placental	 handling	of	DAAs	 are	 solely	 based	on	devel‐
opmental	toxicology	studies	in	animal	models.	As	shown	in	Table	2,	
placental	 transfer	of	sofosbuvir,	daclatasvir,	glecaprevir,	pibrentas‐
vir,	 grazoprevir	 and	 elbasvir	 has	 been	 observed	 in	 rats.	 Placental	
transfer	of	grazoprevir	and	elbasvir	has,	in	addition	to	rats,	also	been	
observed	 in	rabbits,	but	to	a	minimal	extent.	However,	because	of	
interspecies	 differences	 in	 placental	 anatomy,	 placental	 transfer	





3.3 | Prediction of placental drug handling ex vivo
To	predict	transfer	of	drugs	across	the	human	placenta	in	vivo,	data	
from	 animal	 studies	 may	 be	 combined	 with	 information	 on	 drug‐
specific	 physicochemical	 characteristics.	 Comparing	 DAAs	 based	
on	 their	 specific	 physicochemical	 properties	 provides	 information	




of	 drugs	 across	 the	 placental	 barrier.81	 In	 general,	 maternofoetal	
exchange	 increases	 with	 gestational	 age	 because	 of	 physiological	
changes,	 eg	 reduced	 membrane	 thickness	 and	 increased	 uterine	
blood	flow,	inherent	to	the	increased	foetal	demand	of	oxygen	and	
nutrients.80	Passive	diffusion	is	the	major	route	of	placental	transport	
and	 is	 responsible	 for	 rapid	 transfer	of	 lipophilic	drugs	with	a	mo‐
lecular	weight	of	<500	Da.	Larger	molecules	may	also	be	subjected	
to	passive	diffusion,	which	is	a	relatively	slow	process	81;	all	DAAs	
are	highly	 lipophilic,	 indicated	by	a	 log	P	>2.5	 (except	for	sofosbu‐
vir,	log	P	=	1.62),	favouring	effective	passive	diffusion.	On	the	other	
hand,	 their	 high	molecular	weight	 (all	 >500	Da)	may	hamper	or	 at	
least	slow	the	process.	In	addition,	the	degree	of	ionisation	and	pro‐
tein	binding	also	influence	the	rate	and	extent	of	placental	transfer.	
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Protein	binding	will	contribute	 to	 trapping	of	drug	 in	 the	 foetal	or	
maternal	circulation,	and	as	maternal	and	foetal	plasma	protein	con‐
centrations	 differ	 and	 change	with	 advancing	 gestational	 age,	 the	
maternal‐to‐foetal	ratio	of	total	drug	plasma	concentration	may	vary	
accordingly.82	Next	 to	passive	diffusion,	drug	 transport	across	 the	
placental	barrier	may	also	be	carrier‐mediated,	either	as	facilitated	












is	 a	 greater	potential	 of	P‐gp	 substrates	 (eg	most	DAAs),	 to	 reach	
the	unborn	child	with	advancing	gestational	age.	Literature	on	BCRP	
expression	throughout	gestation	is	inconsistent.84
As	outlined	above,	different	 factors	either	 facilitate	or	 impede	
drug	transport	across	 the	placental	barrier.	Hence,	 it	 is	difficult	 to	
estimate	the	extent	of	placental	transport	of	a	specific	drug	at	a	spe‐
cific	time	point	during	pregnancy.	In	addition	to	in	vitro	techniques	
using	 immortalised	 cell	 lines	 or	 tissue	 explants,	 computer‐assisted	
modelling	 attempts	 are	 useful	 to	 explore	 the	 contribution	 of	 the	





TA B L E  2  Safety	data	from	reproductive	teratogenicity	studies	of	DAAs	in	pregnancy










Tested animal species 
(% of maternal plasma 
levels)
Transfer into milka 
(% of maternal 
plasma levels)
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increases	 towards	 term.80	 Therefore,	 data	 from	 ex	 vivo	 placental	







4  | SAFET Y OF DIREC T-AC TING 
ANTIVIR AL S DURING PREGNANCY
In	 the	absence	of	 conclusive	evidence	 from	DAA	exposure	during	
human	 pregnancy,	 assessments	 of	 DAA	 safety	 are	 based	 on	 data	
derived	from	animal	reproduction	toxicology	studies.	Table	2	sum‐
marises	 the	 results	 of	 these	 pre‐clinical	 studies	 on	 embryofoetal	
toxicity,	 teratogenicity,	 placenta	 transfer	 and	 breast	 milk.	 The	 lit‐
erature	search	strategy	can	be	found	in	Appendix	S1.	Although	the	
majority	of	the	adverse	effects	of	drugs	are	related	to	direct	foetal	
exposure	because	of	 placental	 transfer,	 drugs	may	 also	 affect	 the	
developing	 foetus	 indirectly	 by	 disturbing	 placental	 function.89 
However,	 the	 species‐specific	 placental	 physiology,	 as	well	 as	 im‐
munological	 and	 endocrinological	 differences	 hamper	 the	 transla‐
tion	of	placental	drug	effects	from	animal	studies.90	A	large	registry	
of	 infants	 intrauterine‐exposed	to	DAAs	 is	needed	to	assess	 long‐
term	effects	in	humans.	Such	an	approach	has	been	undertaken	for	
HIV,	 the	 Antiretroviral	 Pregnancy	 Registry,	 and	 has	 been	 proven	




The	 only	 data	 available	 on	 sofosbuvir/daclatasvir	 in	 human	 preg‐
nancy	 include	 one	 study	 on	 accidental	 sofosbuvir/daclatasvir	 ex‐
posure	 around	 the	 time	 of	 conception	 (n	 =	 7).	 No	 adverse	 birth	
outcomes	 were	 reported	 but	 one	 infant	 tested	 HCV	 positive	 at	
18	months	with	low	viral	load,	which	is	not	unexpected	as	all	women	
discontinued	therapy	early,	before	week	9	of	gestation.53
Sofosbuvir	 administration	 showed	 no	 adverse	 effects	 in	 pre‐




in	 rats	 are	 based	 on	 exposure	 to	 the	 major	 (inactive)	 metabolite	
GS‐331007.	At	GS‐331007	exposure	levels	following	a	10‐fold	RHD,	
no	effect	on	 intrauterine	development	or	any	malformations	were	
seen	 in	 rats.92,93	 As	 sofosbuvir	 was	 detectable	 in	 human	 plasma,	
data	 from	 rodent	 studies	 regarding	 sofosbuvir	 exposure	 should	
be	 interpreted	with	caution.	For	daclatasvir,	 embryofoetal	 toxicity	
(external	and/or	visceral	malformations)	in	rabbits	and	rats	was	re‐
ported	by	the	EMA.	However,	exposure	in	rats	and	rabbits	was	4.6	











Data	on	 sofosbuvir/ledipasvir	 use	during	pregnancy	 are	 limited	 to	
two	 conference	 abstracts:	 one	 study	 performed	 in	 India	 included	
pregnant	 women	 living	 with	 HCV	 who	 requested	 treatment	 be‐












safe	 for	 the	 developing	 offspring	 in	 rats	 and	 rabbits.	 At	 exposure	
levels	of	3.4‐fold	RHD,	minor	effects	of	ledipasvir	on	fertility	of	fe‐
male	rats	were	reported.	However,	this	was	not	seen	at	2‐fold	RHD	


















be	detected	 in	 litter	 after	 a	 single	dose	of	30	mg/kg	on	gestation	
day	13	or	18.	Maternal	voxilaprevir	administration	did	not	result	in	





headache,	 fatigue	 and	 nausea.	 When	 combined	 with	 voxilapre‐
vir,	 diarrhoea	 and	 nausea	were	 also	 reported	 as	 common	 adverse	
events.58,75
4.4 | Grazoprevir/elbasvir
Grazoprevir	 and	 elbasvir	 reproduction	 studies	 have	 failed	 to	 re‐
















In	 clinical	 studies,	 the	most	 commonly	 reported	 adverse	 reac‐









5  | SAFET Y OF DIREC T-AC TING 
ANTIVIR AL S DURING THE L AC TATION
As	 studies	 have	 shown	 that	 avoidance	 of	 breastfeeding	 does	 not	
































There	are	multiple	 reasons	 to	either	 consider	or	defer	DAA	 treat‐
ment	 during	 pregnancy	 as	 reviewed	 extensively	 by	 others.7,114,115 
Although	the	AASLD/IDSA	guidelines	recommend	universal	screen‐
ing	of	pregnant	women,24	no	DAA	regimen	is	currently	approved	for	
treatment	 during	 pregnancy	 because	 of	 insufficient	 human	 safety	
and	efficacy	data	and	treatment	is	therefore	delayed	until	after	de‐
livery.	The	high	chance	of	loss	to	follow‐up	of	both	mother	and	her	
HCV‐exposed	child	 in	many	settings,	 together	with	 loss	of	health‐
care	insurance	after	pregnancy	may	complicate	adequate	maternal	
and	 paediatric	 treatment,	 highlighting	 the	 pregnancy	 period	 as	 a	
unique	window	of	opportunity	to	both	cure	the	mother	and	prevent	
vertical	transmission	of	HCV.46,116
Standard	dosing	 regimens	of	 currently	used	DAAs	may	be	 sub‐
optimal	 for	 the	 pregnant	 patient	 population	 as	 pregnancy‐induced	
pharmacokinetic	 changes	 may	 influence	 maternal	 drug	 exposure,	
hence	efficacy	of	 the	drugs.	The	expected	 increased	elimination	of	
DAAs,	 both	 because	 of	 a	 potentially	 increased	 biliary	 excretion	 as	




dose—which	 is	 rarely	 done	 in	 clinical	 practice—a	DAA	 combination	
less	prone	to	pregnancy‐induced	effects	could	be	chosen,	if	available.
Apart	 from	data	on	maternal	 exposure	 to	DAAs,	 early	data	on	
placental	handling	and	subsequent	foetal	exposure	are	important	to	
study	possible	placental	toxicity	of	DAAs	as	well	as	the	potential	of	
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DAAs	 to	 provide	 foetal	 pre‐exposure	 prophylaxis.	 Several	 ex	 vivo	














rats	 and/or	 rabbits	when	 administered	 early	 during	 pregnancy.	 In	
clinical	practice,	 it	 is	more	likely	that	treatment	will	be	started	late	




















ment	may	be	 at	 the	end	of	 the	 second	 trimester	 (at	 around	week	
23/24	of	gestation)	or	early	third	trimester	(at	around	27/28	weeks	
of	gestation),	 in	case	of	a	12‐	or	8	week	 treatment	period	 respec‐
tively,	and	may	have	to	be	extended	until	after	delivery	to	complete	







plementation	 of	 treatment	 in	 this	 population.	 Research	 on	 the	 po‐
tential	 effect	 of	maternal	 DAA	 use	 on	 the	 state	 of	 foetal‐directed	
immune	 tolerance	 is	 of	 particular	 importance	 in	 this	 population	 as	
DAAs	are	thought	to	improve	the	proliferative	potential	of	HCV‐spe‐
cific	T	cell	response	again	which	may	decrease	immune	tolerance.120 
Furthermore,	 foetal	 exposure	 should	be	assessed,	 eg	by	measuring	
umbilical	 cord	 blood	 concentrations,	 when	 women	 continue	 treat‐
ment	 until	 after	 delivery.	 This	 information	 is	 needed	 to	 assess	 the	








cause	of	genotype	2	or	3	 infection.52	As	genotyping	 is	 costly,	not	
feasible	 in	 all	 settings	 and	delays	 treatment	 start,	 future	 research	
may	focus	particularly	on	the	use	of	the	pan‐genotypic	DAA	com‐
binations	 glecaprevir/pibrentasvir	 and	 sofosbuvir/velpatasvir	 (with	
or	 without	 voxilaprevir)	 during	 pregnancy.	 Furthermore,	 the	 use	
of	 co‐medication	may	determine	 the	DAA	regimen	of	 first	 choice.	
In	 the	 case	 of	 HCV/HIV	 co‐infection,	 EFV	 should	 not	 be	 used	 in	
combination	with	any	DAA	and	when	boosted	PIs	are	part	of	cART,	
only	sofosbuvir/ledipasvir	or	sofosbuvir/velpatasvir	should	be	used	
concomitantly.	 If	women	use	proton	pump	 inhibitors	 (PPIs)	 during	
pregnancy,	neither	sofosbuvir/ledipasvir	nor	sofosbuvir/velpatasvir	
should	be	prescribed.	In	case	of	concomitant	use	of	strong	CYP3A4	







HCV	 prevalence	 worldwide.121	 Women	 becoming	 pregnant	 using	
daclatasvir	are	advised	to	stop	their	treatment	because	of	the	lack	
of	knowledge	regarding	safety	and	efficacy,53	despite	not	knowing	




on	 daclatasvir	 efficacy	 in	 human	pregnancy	 and	 global	 pregnancy	
registry	databases	are	warranted	to	assess	its	safety.








Treatment	 of	 HCV	 with	 DAAs	 during	 pregnancy	 and	 breastfeed‐
ing	is	not	currently	recommended	because	of	lack	of	data	on	safety,	
leaving	pregnant	women	diagnosed	with	HCV	untreated	until	after	
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delivery	(which	in	itself	maybe	distressing	for	the	mother	and	deter	
her	from	breastfeeding).	In	our	opinion,	this	window	of	opportunity	
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